23 results on '"Niegisch, Günter"'
Search Results
2. Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data.
- Author
-
Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Deiters B, Maywald U, Wilke T, and Kearney M
- Subjects
- Adult, Aged, Humans, Male, Delivery of Health Care, Health Care Costs, Insurance, Health, Retrospective Studies, Female, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
- Abstract
Aims: This retrospective claims data study characterized real-world treatment patterns, healthcare resource utilization (HCRU), and costs in patients with metastatic urothelial carcinoma (mUC) in Germany., Materials and Methods: Continuously insured adults with incident mUC diagnosis (=index; ICD-10 : C65-C68/C77-C79) in 2015-2019 were identified from two German claims databases. Patients who received first-line (1 L) treatment within 12 months of index were divided into three mutually exclusive sub-cohorts: platinum-based chemotherapy (PB-CT), non-PB-CT, and immunotherapy (IO). Patient characteristics were assessed during a 24-month baseline period; treatments, HCRU, and costs (of the health insurance fund) per patient-year (ppy) were described during 12-month follow-up., Results: We identified 3,226 patients with mUC (mean age, 73.8 years; male, 70.8%; mean Elixhauser Comorbidity Index, 17.6); 1,286 (39.9%) received 1 L treatment within 12 months of index. Of these, 825 (64.2%) received PB-CT, 322 (25.0%) non-PB-CT, and 139 (10.8%) IO. On average, treated patients had 5.1 hospitalizations ppy. Most UC-related hospitalizations ppy were observed in the PB-CT cohort (5.8), followed by the non-PB-CT (4.2) and IO (2.3) cohorts. Mean UC-related hospitalization costs ppy were €22,218 in the treated cohort, €24,294 in PB-CT, €19,079 in IO, and €18,530 in non-PB-CT cohorts. Cancer-related prescription costs ppy averaged €6,323 in treated patients, and €25,955 in IO, €4,318 in non-PB-CT, and €4,270 in PB-CT cohorts., Limitations: We recognized limitations in our study's sample selection due to unavailable mUC disease status data. We addressed this through an upstream feasibility study conducted in consultation with clinical experts to determine a suitable proxy. Proxies were also used to delineate treatment lines, switches, and discontinuations due to data absence. Furthermore, due to data restrictions, collective dataset analysis was not possible, prompting a meta-analysis for pooled results., Conclusions: The study shows that mUC is associated with significant HCRU and costs across different types of 1 L systemic therapy.
- Published
- 2024
- Full Text
- View/download PDF
3. Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.
- Author
-
Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, Guenther S, Deiters B, Maywald U, Wilke T, and Kearney M
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Germany epidemiology, Middle Aged, Treatment Outcome, Aged, 80 and over, Urologic Neoplasms mortality, Urologic Neoplasms pathology, Urologic Neoplasms drug therapy, Urologic Neoplasms therapy, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms therapy, Urinary Bladder Neoplasms drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasm Metastasis, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell pathology, Carcinoma, Transitional Cell secondary, Carcinoma, Transitional Cell therapy
- Abstract
Aim: This study assessed real-world treatment in patients with metastatic urothelial carcinoma (mUC) in Germany. Materials & methods: Patients diagnosed with mUC from 2015 to 2019 were identified in two claims databases: AOK PLUS and GWQ. Results: 3226 patients with mUC were analyzed; 1286 (39.9%) received systemic treatment within 12 months of diagnosis (platinum-based chemotherapy: 64.2%). Factors associated with receiving treatment were: younger age, male sex, less comorbidity and recent diagnosis. In AOK PLUS and GWQ populations, unadjusted median overall survival (interquartile range) from diagnosis in treated patients was 13.7 (6.8-32.9) and 13.8 (7.1-41.7) months, and in untreated patients was 3.0 (1.2-10.8) and 3.6 (1.2-18.8) months, respectively. Conclusion: A significant proportion of patients with mUC in Germany receive no systemic treatment.
- Published
- 2024
- Full Text
- View/download PDF
4. Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
- Author
-
Váradi M, Horváth O, Módos O, Fazekas T, Grunewald CM, Niegisch G, Krafft U, Grünwald V, Hadaschik B, Olah C, Maráz A, Furka A, Szűcs M, Nyirády P, and Szarvas T
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Retrospective Studies, Radioimmunotherapy, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
- Abstract
Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
5. Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
- Author
-
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, and Zengerling F
- Subjects
- Adult, Humans, Male, Female, Middle Aged, Aged, Nivolumab adverse effects, Ipilimumab adverse effects, Platinum, Immunotherapy adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms
- Abstract
Background: Nivolumab is used after platinum-based chemotherapy in patients with metastatic urothelial carcinoma. Studies suggest improved outcomes for dual checkpoint inhibition with high ipilimumab doses. We aimed to examine the safety and activity of nivolumab induction and high-dose ipilimumab as an immunotherapeutic boost as a second-line treatment for patients with metastatic urothelial carcinoma., Methods: TITAN-TCC is a multicentre, single-arm, phase 2 trial done at 19 hospitals and cancer centres in Germany and Austria. Adults aged 18 years or older with histologically confirmed metastatic or surgically unresectable urothelial cancer of the bladder, urethra, ureter, or renal pelvis were eligible. Patients had to have progression during or after first-line platinum-based chemotherapy and up to one more second-line or third-line treatment, a Karnofsky Performance Score of 70 or higher, and measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1. After four doses of intravenous nivolumab 240 mg induction monotherapy every 2 weeks, patients with a partial or complete response at week 8 continued maintenance nivolumab, whereas those with stable or progressive disease (non-responders) at week 8 received a boost of two or four doses of intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks. Patients who subsequently had progressive disease during nivolumab maintenance also received a boost, using this schedule. The primary endpoint was the confirmed investigator-assessed objective response rate in the intention-to-treat population and had to exceed 20% for the null hypothesis to be rejected (based on the objective response rate with nivolumab monotherapy in the CheckMate-275 phase 2 trial). This study is registered with ClinicalTrials.gov, NCT03219775, and is ongoing., Findings: Between April 8, 2019, and Feb 15, 2021, 83 patients with metastatic urothelial carcinoma were enrolled and all received nivolumab induction treatment (intention-to-treat population). The median age of enrolled patients was 68 years (IQR 61-76), and 57 (69%) were male and 26 (31%) were female. 50 (60%) patients received at least one boost dose. A confirmed investigator-assessed objective response was recorded in 27 (33%) of 83 patients in the intention-to-treat population, including six (7%) patients who had a complete response. This objective response rate was significantly higher than the prespecified threshold of 20% or less (33% [90% CI 24-42]; p=0·0049). The most common grade 3-4 treatment-related adverse events were immune-mediated enterocolitis (nine [11%] patients) and diarrhoea (five [6%] patients). Two (2%) treatment-related deaths were reported, both due to immune-mediated enterocolitis., Interpretation: Treatment with nivolumab and nivolumab plus ipilimumab boosts in early non-responders and patients who progress late significantly improved objective response rate after previous platinum-based chemotherapy compared with the rate reported with nivolumab in the CheckMate-275 trial. Our study provides evidence for the added value of high-dose ipilimumab 3 mg/kg and suggests a potential role for the combination as a rescue strategy in platinum-pretreated patients with metastatic urothelial carcinoma., Funding: Bristol Myers Squibb., Competing Interests: Declaration of interests M-OG received funding for this trial and for medical writing from Bristol Myers Squibb; grants or contracts as research or institutional funding from Bristol Myers Squibb, Intuitive Surgical, and Bayer Vital; personal consulting fees from AstraZeneca, Bristol Myers Squibb, Ipsen, MSD, Pfizer, Astellas Pharma, EUSA Pharma Merck Serono, Roche Pharma, Takeda, Eisai, Bayer Vital, Janssen, and Gilead; personal honoraria from AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Ipsen, Merck Serono, EUSA Pharma, Janssen, and Astellas Pharma; and personal support for attending meetings or travel (or both) from Merck Serono and Bristol Myers Squibb. CBG received payment for a marketing survey from Dr Rönsberg Health Marketing Intelligence and participation on an advisory board from Bayer Vital. GN received personal consulting fees from Roche; payments or honoraria for a manuscript from Ingress Health and for lectures from Astellas, AstraZeneca, Bristol Myers Squibb, Pfizer, and Roche; support for attending meetings or travel (or both) from Merck, Roche, Pfizer, and Bristol Myers Squibb; and personal payments for advisory boards from Bristol Myers Squibb, Ipsen, Janssen, Merck, Pfizer, and Roche. MP received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Bristol Myers Squibb. FR received consulting fees from Roche, Janssen, Merck, and QED Therapeutics; payment or honoraria for lectures, presentations, speakers bureaus', manuscript writing, or educational events from Roche, Janssen, Merck, MSD, QED Therapeutics, and Astellas Pharma; support for attending meetings or travel (or both) from Janssen and Merck; and participation on a data safety monitoring board or advisory board from Merck, Bristol Myers Squibb, MSD, and Roche. CB received grants or contracts from AstraZeneca, Cepheid, Erbe Elektromedizin, and Janssen-Cilag; consulting fees from Roche Pharma and Bristol Myers Squibb; and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AstraZeneca, Bayer, Janssen-Cilag, Medac, and Roche Pharma. KL received payment for manuscript writing from Bristol Myers Squibb and institutional funding from Intuitive Surgical. MartS received grants or contracts as research or institutional funding from Bristol Myers Squibb, Bayer Vital, AstraZeneca, Ipsen, MSD, Janssen, and Sanofi; personal consulting fees from AstraZeneca, Bristol Myers Squibb, Ipsen, MSD, Pfizer, Astellas Pharma, Janssen, Bayer Vital, EDAP TMS, and Sanofi; personal honoraria from AstraZeneca (MedImmune), Bayer, Merck, Pfizer, Janssen, and Merck Serono; and personal support for attending meetings or travel (or both) from AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Sanofi, Merck, EDAP TMS, and Bayer. FZ received consulting fees from Apogepha Pharma, Astellas Pharma, AstraZeneca Germany, Bayer Vital, Bristol Myers Squibb, Ipsen Pharma, Janssen-Cilag, Merck Healthcare Germany, Pfizer Pharma, and Roche Pharma; payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Astellas Pharma, Bayer Vital, Ipsen Pharma, Janssen-Cilag, Merck Healthcare Germany, Pfizer Pharma, and Sanofi-Aventis Germany; and support for attending meetings or travel (or both) from Astellas Pharma, Ipsen Pharma, Janssen-Cilag, and Pfizer Pharma. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
6. Epigenetic Priming and Development of New Combination Therapy Approaches.
- Author
-
Meneceur S, Grunewald CM, Niegisch G, and Hoffmann MJ
- Subjects
- Animals, Histones metabolism, Cisplatin therapeutic use, DNA Methylation, Epigenesis, Genetic, Chromatin genetics, Histone Deacetylase Inhibitors pharmacology, Histone Deacetylase Inhibitors therapeutic use, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms drug therapy, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use
- Abstract
Muscle-invasive urothelial carcinoma of the bladder (MIBC) has been treated with cisplatin-based chemotherapy for over 30 years. With the advent of immune checkpoint inhibitors, antibody drug conjugates and FGFR3 inhibitors new therapeutic options have been approved for patients with urothelial carcinoma (UC) and are still under investigation regarding association between patients' response and recently defined molecular subtypes. Unfortunately, similar to chemotherapy, only a fraction of UC patients responds to these new treatment approaches. Thus, either further new efficacious therapeutic options for treatment of individual subtypes or new approaches to overcome treatment resistance and to increase patients' response to standard of care treatment are needed.Epigenetic modifications of DNA and chromatin are known to mediate cellular plasticity or treatment resistance, and the responsible epigenetic regulators are frequently mutated or aberrantly expressed in UC. Thus, these enzymes provide targets for novel drug combination therapies to "episensitize" toward approved standard therapies by epigenetic priming. In general, these epigenetic regulators comprise writers and erasers like DNA methyltransferases and DNA demethylases (for DNA methylation), histone methyltransferases and histone demethylases (for histone methylation), as well as acetyl transferases and histone deacetylases (for histone and nonhistone acetylation). Such modifications, e.g., acetyl groups, are recognized by further epigenetic reader proteins, e.g., like the bromodomain and extra-terminal domain (BET) family proteins that often interact in multi-protein complexes and finally regulate chromatin conformation and transcriptional activity.Concurringly, epigenetic regulators target a plethora of cellular functions. Their pharmaceutical inhibitors often inhibit enzymatic activity of more than one isoenzyme or may have further noncanonical cytotoxic effects. Thus, analysis of their functions in UC pathogenesis as well as of the antineoplastic capacity of corresponding inhibitors alone or in combination with other approved drugs should follow a multidimensional approach. Here, we present our standard approach to analyze cellular effects of new epigenetic inhibitors on UC cells alone to define their potency and to conclude on putative reasonable combination therapy partners. We further describe our approach to identify efficacious synergistic combination therapies (e.g., with cisplatin or PARP inhibitors) that may have reduced normal toxicity through dose reduction, which can then be further analyzed in animal experiments. This approach may also serve as prototype for the preclinical evaluation of other epigenetic treatment approaches., (© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
7. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
- Author
-
Niegisch G
- Subjects
- Humans, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell secondary, Immunoconjugates pharmacology, Immunoconjugates therapeutic use, Immunoconjugates chemistry, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology
- Abstract
Antibody drug conjugates (ADC) are a new class of agents that have been expanding the spectrum of treatment options in metastatic urothelial carcinoma only recently. Preliminary data suggest that these compounds may have the potential even to replace current standard treatments as platinum-based chemotherapies. To this end, current and future preclinical and translational evaluation of novel treatment strategies should consider these novel compounds in addition to current standard options as well. In this context, the following article will provide an overview of this new class of agents, starting with general information on molecular structure and mode of action, clinical use of ADCs in urothelial carcinoma, and ending with considerations for designing preclinical and translational experiments implementing ADCs., (© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
8. Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).
- Author
-
Hegmann L, Sturm S, Niegisch G, Windolf J, and Suschek CV
- Subjects
- Humans, Mitomycin pharmacology, Mitomycin therapeutic use, Antibiotics, Antineoplastic, Urinary Bladder, Reactive Oxygen Species, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell pathology
- Abstract
Human urothelial bladder carcinoma (uBC) is the second most tumor entity of the urogenital tract. As far as possible, therapy for non-muscle invasive uBC takes place as resection of the tumor tissue, followed by intravesical chemotherapy or immunotherapy. Because of the high recurrence rate of uBC, there is a need for improved efficiency in the treatment. In the present in vitro study we have evaluated a new approach to enhance the cytotoxic efficiency of Mitomycin C (MMC), which is commonly used for intravesical treatment of uBC on the relevant urothelial cancer cell line RT112. For that we used quasi-monochromatic blue light (453 ± 10 nm) at its non-toxic dose of 110 J/cm
2 as an additive stimulus to enhance the therapeutic efficiency of MMC (10 μg/ml). We found, that blue light exposure of RT112 cells led to a very strong increase in intracellular production of reactive oxygen species (ROS) and to a significant reduction (p < 0.05) of all function parameters of mitochondrial respiration, including basal activity and ATP production. Although not being toxic when used as a single impact, together with MMC blue light strongly enhanced the therapeutic efficiency of MMC in the form of significantly enhanced cytotoxicity via apoptosis and secondary necrosis. Our results clearly show that blue light, most likely due to its ability to increase intracellular ROS production and reduce mitochondrial respiration, increased the cytotoxic efficiency of MMC and therefore might represent an effective, low-side-effect, and success-enhancing therapy option in the local treatment of bladder cancer., Competing Interests: Declaration of Competing Interest None., (Copyright © 2022 Elsevier B.V. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
9. Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression.
- Author
-
Jaguva Vasudevan AA, Hoffmann MJ, Poschmann G, Petzsch P, Wiek C, Stühler K, Köhrer K, Schulz WA, and Niegisch G
- Subjects
- Cell Line, Tumor, Humans, Proteomics, Transcriptome, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell metabolism, Histone Deacetylases genetics, Histone Deacetylases metabolism, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms metabolism
- Abstract
Urothelial carcinoma (UC) of the urinary bladder is a prevalent cancer worldwide. Because histone deacetylases (HDACs) are important factors in cancer, targeting these epigenetic regulators is considered an attractive strategy to develop novel anticancer drugs. Whereas HDAC1 and HDAC2 promote UC, HDAC5 is often downregulated and only weakly expressed in UC cell lines, suggesting a tumor-suppressive function. We studied the effect of stable lentiviral-mediated HDAC5 overexpression in four UC cell lines with different phenotypes (RT112, VM-Cub-1, SW1710, and UM-UC-3, each with vector controls). In particular, comprehensive proteomics and RNA-seq transcriptomics analyses were performed on the four cell line pairs, which are described here. For comparison, the immortalized benign urothelial cell line HBLAK was included. These datasets will be a useful resource for researchers studying UC, and especially the influence of HDAC5 on epithelial-mesenchymal transition (EMT). Moreover, these data will inform studies on HDAC5 as a less studied member of the HDAC family in other cell types and diseases, especially fibrosis., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
10. [Metastatic urothelial carcinoma-guideline-based therapy and new options].
- Author
-
Niegisch G, von Amsberg G, Rehlinghaus M, Grunewald CM, and Retz M
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Immune Checkpoint Inhibitors, Immunotherapy, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms drug therapy
- Abstract
Due to the approval of immuno-oncological therapies with immune checkpoint inhibitors, the treatment of metastatic urothelial carcinoma has become more complex in all lines of therapy. Thus, in first-line treatment, immunotherapy alone or immune maintenance therapy following platinum-based chemotherapy can be applied in addition to treatment with platinum-based combination therapies alone. In addition to the approval status and guideline recommendation, patient-specific factors such as comorbidities as well as patient preference must always be considered when choosing a therapy. In the following, we summarize the current data on treatment options in the first-line therapy of metastatic urothelial carcinoma and illustrate their practical application using a patient example., (© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
11. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.
- Author
-
Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Lucianò R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, and Necchi A
- Subjects
- Cystectomy, Epithelial Cells, Humans, Neoadjuvant Therapy, Retrospective Studies, Carcinoma, Transitional Cell surgery, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms surgery
- Abstract
Background: Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with different histologic variants (HVs)., Patients and Methods: We relied on a retrospective, multicenter database of 2858 patients with BCa who had undergone radical cystectomy with or without NAC from 1990 to 2017. Pure and mixed HVs were grouped into 6 categories: squamous cell carcinoma (SCC; n = 283; 45%), other subtypes (n = 95; 15%), micropapillary (n = 85; 14%), adenocarcinoma (n = 65; 10%), small cell (n = 54; 8.6%), and sarcomatous (n = 47; 7.6%). Kaplan-Meier and Cox regression analyses were used to examine cancer-specific survival (CSS) according to the HV, using pure UC as the reference. Logistic regression models were used to examine the odds of clinical-to-pathologic downstaging after NAC according to the HV., Results: Overall, we identified 2229 cases of pure UC and 629 cases of BCa with HVs at radical cystectomy. Of the 450 NAC-treated patients, only those patients with SCC (n = 44; 9.8%) had had worse CSS (median CSS, 33 vs. 116 months; P < .001) and higher mortality rates (hazard ratio, 2.1; P = .03) compared with those with pure UC (n = 328; 72.9%). The results of the analyses were also confirmed when the pure and mixed cases were considered separately. After adjusting for NAC, only SCC showed a lower rate of clinical-to-pathologic downstaging (odds ratio, 0.4; P = .03) compared with UC., Conclusions: SCC was the HV exhibiting the lowest effect of NAC in terms of activity and CSS. Compared with pure UC, SCC seemed to be insensitive to traditional NAC regimens., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
12. [Systemic therapy for metastatic urothelial carcinoma - Current status and what comes after checkpoint inhibitors?]
- Author
-
Grunewald CM, Hiester A, and Niegisch G
- Subjects
- Antineoplastic Agents therapeutic use, Cisplatin therapeutic use, Europe, Humans, Immunotherapy, Nivolumab therapeutic use, Carcinoma, Transitional Cell drug therapy, Urinary Bladder Neoplasms drug therapy
- Abstract
The increasing knowledge of the influence of the immune system on tumour development and progression has fundamentally changed our understanding of tumour biology in recent years. While the available treatment options for patients with metastatic urothelial carcinoma of the urinary bladder have hardly improved over decades, the advent of immune checkpoint inhibitors has caused major changes in the corresponding treatment landscape.Although cisplatin-based combination therapies remain the main element, additional effective treatment options now exist with the PD-(L)-1 inhibitors atezolizumab, pembrolizumab and nivolumab, which have been approved in Europe. A remarkable long-term response is balanced by the occurrence of occasionally severe immune-mediated side effects and an overall low response rate of approximately 25 %. A large number of current clinical trials therefore address possible combinatory approaches in order to make optimal use of possible synergisms and additive effects of the substances available to date, taking into account an acceptable side effect profile. In addition, many new therapeutic approaches are also being tested in clinical trials. In this context, developments in the field of antibody-drug conjugates and FGFR inhibitors with regards to the very recent FDA approvals are particularly noteworthy.The present review provides an overview of currently available treatment options in metastatic urothelial carcinoma of the bladder and especially focuses on future therapeutic approaches based on current clinical trials., Competing Interests: GN: Vortragstätigkeiten: Pfizer Pharma GmbH (seit 2016), Roche Pharma AG (seit 2016), medac GmbH (seit 2017) Advisory Boards, Beratertätigkeit: Roche Parma AG (seit 2015), IMS Health AG (2016-2018), BMS AG (2016), Sanofi-Aventis (2018) Reisekosten- und Fortbildungsunterstützung: Roche Parma AG (seit 2015), medac GmbH (seit 2017), Pfizer Pharma GmbH (seit 2016), (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2020
- Full Text
- View/download PDF
13. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.
- Author
-
Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, and Necchi A
- Subjects
- Aged, Databases, Factual, Humans, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Carcinoma, Transitional Cell surgery
- Abstract
Background: The effect of local treatment on survival in advanced-stage patients has gained interest in several malignancies; however, limited data exist regarding urothelial carcinoma (UC)., Objective: To test the impact of surgery of the primary tumor site on cancer-specific mortality (CSM) and overall mortality (OM) in patients affected by metastatic UC., Design, Setting, and Participants: Individual patient-level data from a multicenter collaboration, including metastatic UC patients treated with first-line cisplatin- or carboplatin-based chemotherapy administered between January 2006 and January 2011 from hospitals in the USA, Europe, Israel, and Canada., Outcome Measurements and Statistical Analysis: Univariable and multivariable Cox regression analyses were used to assess the effect of surgery on CSM and OM in patients affected by metastatic UC using 3-mo landmark analyses. Subgroup analyses were performed on the basis of the number of metastasis sites involved and including only patients treated with surgery before the start of chemotherapy., Results and Limitations: Of the 326 patients included in the study, 47 (14%) were treated with surgery of the primary tumor site. Median (interquartile range) follow-up was 43 (33-45)mo. Of the patients treated with surgery, 28 (60%) were affected by a primary bladder cancer and 19 (40%) by a primary upper urinary tract tumor. On multivariable analyses, surgery was associated with a protective effect on CSM (hazard ratio [HR]: 0.59, confidence interval [CI]: 0.35-0.98, p=0.04) and OM (HR: 0.45, CI: 0.37-0.99, p=0.04) compared with patients treated with chemotherapy only. Similar results were found considering patients only surgically treated before the start of chemotherapy. After stratifying according to the number of metastatic sites, surgery has an effect on survival in patients with only one metastatic site, while no survival benefit was observed in patients with two or more metastatic sites. The study is limited by its retrospective nature., Conclusions: We found that surgery of the primary tumor site is associated with improved survival in patients with metastatic UC who received standard chemotherapy. This effect disappears in patients affected by two or more metastatic sites. Our results need to be validated in a high-quality prospective trial., Patient Summary: In our multicenter, retrospective series, surgery in metastatic urothelial cancer patients improve survival compared with patients treated with chemotherapy only. This effect was evident in patients with limited disease extent, identified as one metastatic site., (Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
14. [Personalised medicine in urothelial bladder cancer].
- Author
-
Grunewald CM and Niegisch G
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, B7-H1 Antigen genetics, Carcinoma, Papillary genetics, Carcinoma, Papillary pathology, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell pathology, Cisplatin administration & dosage, Combined Modality Therapy, Cystectomy, DNA Mutational Analysis, Humans, Immunotherapy methods, Neoplasm Invasiveness genetics, Neoplasm Metastasis, Prognosis, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology, Carcinoma, Papillary therapy, Carcinoma, Transitional Cell therapy, Precision Medicine, Urinary Bladder Neoplasms therapy
- Abstract
Available treatment options and outcomes for patients suffering from urothelial bladder cancer, especially in the metastatic stage, have hardly improved over decades. However, the increasing use of high-throughput analyses and the concept of immune surveillance against tumours have recently changed our understanding of tumour biology in terms of tumour development and progression. Our knowledge of genetic mutations and molecular subtypes provides the possibility of tailor-made therapeutic approaches for patients suffering from bladder cancer. For example, changes in DNA repair signalling pathways are possible predictors of chemotherapy response, and targeted therapies using FGFR or PARP inhibitors are currently being tested in clinical trials. The extent to which molecular subtypes will find their way into clinical practice depends on the prospective evaluation of their prognostic and predictive value. The introduction of immune checkpoint inhibitors is probably the most significant expansion of available treatment options in bladder cancer. Despite their promising results, however, a lot of questions remain to be answered, as only 25 % of patients respond. Again, this highlights the need for predictive biomarkers. The large inter- and intratumoural heterogeneity represents a particular challenge for the clinical implementation of personalised treatment options in bladder cancer. All in all, some important steps towards personalised medicine in urothelial bladder cancer have been taken in the past few years, but, for the most part, their prospective evaluation is still pending., Competing Interests: C.M. Grunewald: keine Interessenkonflikte G. Niegisch: Referententätigkeit: Pfizer Pharma GmbH (seit 2016), Pierre Fabre Pharma GmbH (2016), Roche Pharma AG (seit 2016), medac GmbH (seit 2017), Advisory Boards/beratende Tätigkeit: Roche Parma AG (seit 2015), IMS Health AG (seit 2016), BMS AG (2016), (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2019
- Full Text
- View/download PDF
15. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
- Author
-
Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, and Necchi A
- Subjects
- Aged, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell pathology, Chemotherapy, Adjuvant, Clinical Trials, Phase II as Topic, Cystectomy, Disease-Free Survival, Endpoint Determination, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Risk Factors, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms pathology, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell surgery, Nomograms, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms surgery
- Abstract
Background: Several ongoing phase 2 trials are evaluating new neoadjuvant therapy regimens in patients with muscle-invasive bladder cancer (MIBC). The 1-yr recurrence-free survival (RFS) after radical cystectomy (RC), with or without perioperative chemotherapy, can be used to model statistical assumptions and interpret outcomes from these studies., Objective: To provide a benchmark for predicting 1-yr RFS in patients with cT2-4N0 MIBC., Design, Setting, and Participants: We identified 950 patients with clinical stage T2-4N0 MIBC undergoing RC at 27 centers between 1990 and 2016. We assessed 1-yr RFS rates for patients managed with no perioperative chemotherapy, neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), or NAC followed by AC. Cox regression analyses tested for 1-yr postsurgical RFS predictors. A Cox-based nomogram was developed to estimate 1-yr RFS and its accuracy was assessed in terms of Harrell's c-index, a calibration plot, and decision curve analysis. We report 1-yr RFS rates across the nomogram tertiles., Results and Limitations: The 1-yr RFS rates were 67.9% (95% confidence interval [CI] 64-72) after no perioperative chemotherapy, 76.9% (95% CI 72-83%) after NAC, 77.8% (95% CI 71-85%) after AC, and 57% (95% CI 37-87) after NAC+AC. On multivariable analysis, positive surgical margins (p=0.002), pT stage (p<0.0001), and pN stage (p<.0001) were significantly associated with RFS, while NAC was not (p=0.6). The model including all these factors yielded a c-index of 0.76 (95% CI 0.72-0.79), good calibration, and a high net benefit. The 1-yr RFS rates across nomogram tertiles were 90.5% (95% CI 87-94%), 73.4% (95% CI 68-79%), and 51.1% (95% CI 45-58%), respectively. The results lack external validation., Conclusions: Benchmark 1-yr RFS estimates for phase 2 design of new neoadjuvant trials are proposed and can be used for statistical assumptions, pending external validation., Patient Summary: Our prognostic model predicting 1-yr survival free from recurrence of bladder cancer after radical cystectomy, with or without standard chemotherapy, could provide an improvement to the quality of phase 2 clinical trial designs and interpretation of their results., (Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
16. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
- Author
-
Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, and Niegisch G
- Subjects
- Carcinoma, Transitional Cell drug therapy, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, DNA Methylation, Drug Screening Assays, Antitumor, Gene Expression Regulation, Neoplastic drug effects, HEK293 Cells, Histone Deacetylase Inhibitors chemistry, Histone Deacetylases chemistry, Humans, Molecular Docking Simulation, Urinary Bladder Neoplasms drug therapy, Vorinostat chemistry, Carcinoma, Transitional Cell genetics, Histone Deacetylase Inhibitors pharmacology, Histone Deacetylases genetics, Urinary Bladder Neoplasms genetics, Vorinostat pharmacology
- Abstract
Background: Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investigated the novel HDACi 19i (LMK235) with presumed preferential activity against class IIA HDAC4/5 in comparison to the pan-HDACi vorinostat (SAHA) and the HDAC4-specific HDACi TMP269 in UC cell lines with basal expression of HDAC4 and characterized two HDAC4-overexpressing UC cell lines., Methods: Cytotoxic concentrations 50% (CC
50 s) for HDACi were determined by MTT assay and high-content analysis-based fluorescent live/dead assay in UC cell lines with different expression of HDAC4 and as well as in normal urothelial cell cultures, HBLAK and HEK-293 cell lines. Effects of HDACis were analyzed by flow cytometry; molecular changes were followed by qRT-PCR and Western blots. UC lines overexpressing HDAC4 were established by lentiviral transduction. Inhibitor activity profiles of HDACi were obtained by current state in vitro assays, and docking analysis was performed using an updated crystal structure of HDAC4., Results: In UC cell lines, 19i CC50 s ranged around 1 μM; control lines were similarly or less sensitive. Like SAHA, 19i increased the G2/M-fraction, disturbed mitosis, and elicited apoptosis or in some cells senescence. Thymidylate synthase expression was diminished, and p21CIP1 was induced; global histone acetylation and α-tubulin acetylation also increased. In most cell lines, 19i as well as SAHA induced HDAC5 and HDAC4 mRNAs while rather repressing HDAC7. UC cell lines overexpressing HDAC4 were not significantly less sensitive to 19i. Reevaluation of the in vitro HDAC isoenzyme activity inhibition profile of 19i and its docking to HDAC4 using current assays suggested rather low activity against class IIA HDACs. The specific class IIA HDAC inhibitor TMP269 impeded proliferation of UC cell lines only at concentrations > 10 μM., Conclusions: Anti-neoplastic effects of 19i on UC cells appear to be exerted by targeting class I HDACs. In fact, HDAC4 may rather impede UC growth. Our results suggest that targeting of class IIA HDACs 4/5 may not be optimal for UC therapy. Moreover, our investigation provides further evidence for cross-regulation of class IIA HDACs by class I HDACs.- Published
- 2018
- Full Text
- View/download PDF
17. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
- Author
-
Schlütermann D, Skowron MA, Berleth N, Böhler P, Deitersen J, Stuhldreier F, Wallot-Hieke N, Wu W, Peter C, Hoffmann MJ, Niegisch G, and Stork B
- Subjects
- Antineoplastic Combined Chemotherapy Protocols pharmacology, Apoptosis drug effects, Carcinoma, Transitional Cell pathology, Cell Line, Tumor, Cell Survival drug effects, Cisplatin pharmacology, Cisplatin therapeutic use, Class III Phosphatidylinositol 3-Kinases metabolism, Drug Resistance, Neoplasm drug effects, Drug Synergism, Humans, Up-Regulation, Urinary Bladder Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Autophagy drug effects, Carcinoma, Transitional Cell drug therapy, Class III Phosphatidylinositol 3-Kinases antagonists & inhibitors, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Cisplatin-based regimens are routinely employed for the treatment of urothelial carcinoma. However, therapeutic success is hampered by the primary presence of or the development of cisplatin resistance. This chemoresistance is executed by multiple cellular pathways. In recent years, the cellular process of autophagy has been identified as a prosurvival pathway of cancer cells. On the one hand, autophagy enables cancer cells to survive conditions of low oxygen or nutrient supply, frequently found in tumors. On the other hand, autophagy supports chemoresistance of cancer cells. Here, we aimed at investigating the involvement of autophagy for cisplatin resistance in different urothelial carcinoma cell lines., Materials & Methods: We analyzed the expression levels of different autophagy-related proteins in cisplatin-sensitive and cisplatin-resistant urothelial carcinoma cell lines. Furthermore, we performed cell viability assays and caspase activity assays with cells treated with cisplatin, non-specific or specific autophagy inhibitors (chloroquine, 3-methyladenine, SAR405) or combinations thereof., Results: We found that autophagy-related proteins are up-regulated in different cisplatin-resistant urothelial carcinoma cells compared to the sensitive parental cell lines. Furthermore, inhibition of autophagy, in general, or of the autophagy-inducing class III PtdIns3K complex, in particular, sensitized both sensitive and resistant urothelial carcinoma cells to cisplatin-induced cytotoxic effects., Conclusion: We propose that targeting the autophagic machinery might represent a suitable approach to complement or even increase cisplatin efficacy in order to overcome cisplatin resistance in urothelial carcinoma., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
18. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
- Author
-
Hölscher AS, Schulz WA, Pinkerneil M, Niegisch G, and Hoffmann MJ
- Subjects
- Carcinoma, Transitional Cell drug therapy, Cell Cycle Checkpoints, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Cyclin-Dependent Kinase Inhibitor p57 genetics, Dose-Response Relationship, Drug, Drug Synergism, Gene Expression Regulation, Neoplastic drug effects, Histone Deacetylases metabolism, Humans, Nuclear Proteins genetics, Nuclear Proteins metabolism, Transcription Factors genetics, Transcription Factors metabolism, Urinary Bladder Neoplasms drug therapy, Azepines pharmacology, Carcinoma, Transitional Cell metabolism, Cyclin-Dependent Kinase Inhibitor p57 metabolism, Depsipeptides pharmacology, Triazoles pharmacology, Urinary Bladder Neoplasms metabolism
- Abstract
Background: New efficient therapies for urothelial carcinoma (UC) are urgently required. Small-molecule drugs targeting chromatin regulators are reasonable candidates because these regulators are frequently mutated or deregulated in UC. Indeed, in previous work, Romidepsin, which targets class I histone deacetylases (HDAC), efficiently killed UC cells, but did not elicit canonical apoptosis and affected benign urothelial cells indiscriminately. Combinations of HDAC inhibitors with JQ1, an inhibitor of bromodomain-containing acetylation reader proteins like BRD4, which promote especially the transcription of pro-tumorigenic genes, have shown efficacy in several tumor types. We therefore investigated the effects of combined Romidepsin and JQ1 treatment on UC and benign urothelial control cells., Results: JQ1 alone induced cell cycle arrest, but only limited apoptosis in eight UC cell lines with strongly varying IC
50 values between 0.18 and 10 μM. Comparable effects were achieved by siRNA-mediated knockdown of BRD4. Romidepsin and JQ1 acted in a synergistic manner across all UC cell lines, efficiently inhibiting cell cycle progression, suppressing clonogenic growth, and inducing caspase-dependent apoptosis. Benign control cells were growth-arrested without apoptosis induction, but retained long-term proliferation capacity. In UC cells, anti-apoptotic and oncogenic factors Survivin, BCL-2, BCL-XL, c-MYC, EZH2 and SKP2 were consistently downregulated by the drug combination and AKT phosphorylation was diminished. Around the transcriptional start sites of these genes, the drug combination enhanced H3K27 acetylation, but decreased H3K4 trimethylation. The cell cycle inhibitor CDKN1C/p57KIP2 was dramatically induced at mRNA and protein levels. However, Cas9-mediated CDKN1C/p57KIP2 knockout did not rescue UC cells from apoptosis., Conclusion: Our results demonstrate significant synergistic effects on induction of apoptosis in UC cells by the combination treatment with JQ1 and Romidepsin, but only minor effects in benign cells. Thus, this study established a promising new small-molecule combination therapy approach for UC., Competing Interests: Not applicableNot applicableThe authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.- Published
- 2018
- Full Text
- View/download PDF
19. Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?
- Author
-
Niegisch G and Albers P
- Subjects
- Humans, Urologic Neoplasms, Carcinoma, Transitional Cell, TOR Serine-Threonine Kinases
- Published
- 2017
- Full Text
- View/download PDF
20. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
- Author
-
Isono M, Hoffmann MJ, Pinkerneil M, Sato A, Michaelis M, Cinatl J Jr, Niegisch G, and Schulz WA
- Subjects
- Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell genetics, Caspases metabolism, Cell Cycle drug effects, Cell Line, Tumor, Cell Survival drug effects, Checkpoint Kinase 1 genetics, Checkpoint Kinase 1 metabolism, Checkpoint Kinase 2 genetics, Checkpoint Kinase 2 metabolism, DNA Damage, Deoxycytidine pharmacology, Drug Screening Assays, Antitumor, Drug Synergism, Gene Expression Regulation, Neoplastic drug effects, Humans, Poly(ADP-ribose) Polymerases metabolism, RNA, Small Interfering, Urea pharmacology, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms genetics, Gemcitabine, Antimetabolites, Antineoplastic pharmacology, Carcinoma, Transitional Cell metabolism, Deoxycytidine analogs & derivatives, Protein Kinase Inhibitors pharmacology, Thiophenes pharmacology, Urea analogs & derivatives, Urinary Bladder Neoplasms metabolism
- Abstract
Background: More effective chemotherapies are urgently needed for bladder cancer, a major cause of morbidity and mortality worldwide. We therefore explored the efficacy of the combination of gemcitabine and AZD7762, a checkpoint kinase 1/2 (CHK1/2) inhibitor, for bladder cancer., Methods: Viability, clonogenicity, cell cycle distribution and apoptosis were assessed in urothelial cancer cell lines and various non-malignant urothelial cells treated with gemcitabine and AZD7762. DNA damage was assessed by γH2A.X and 53-BP1 staining and checkpoint activation was followed by Western blotting. Pharmacological inhibition of CHK1 and CHK2 was compared to downregulation of either CHK1 or CHK2 using siRNAs., Results: Combined use of gemcitabine and AZD7762 synergistically reduced urothelial carcinoma cell viability and colony formation relative to either single treatment. Non-malignant urothelial cells were substantially less sensitive to this drug combination. Gemcitabine plus AZD7762 inhibited cell cycle progression causing cell accumulation in S-phase. Moreover, the combination induced pronounced levels of apoptosis as indicated by an increase in the fraction of sub-G1 cells, in the levels of cleaved PARP, and in caspase 3/7 activity. Mechanistic investigations showed that AZD7762 treatment inhibited the repair of gemcitabine-induced double strand breaks by interference with CHK1, since siRNA-mediated depletion of CHK1 but not of CHK2 mimicked the effects of AZD7762., Conclusions: AZD7762 enhanced sensitivity of urothelial carcinoma cells to gemcitabine by inhibiting DNA repair and disturbing checkpoints. Combining gemcitabine with CHK1 inhibition holds promise for urothelial cancer therapy.
- Published
- 2017
- Full Text
- View/download PDF
21. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
- Author
-
Höhn A, Krüger K, Skowron MA, Bormann S, Schumacher L, Schulz WA, Hoffmann MJ, Niegisch G, and Fritz G
- Subjects
- Apoptosis drug effects, Apoptosis genetics, Carcinoma, Transitional Cell pathology, Cell Line, Tumor, Cell Survival drug effects, Cell Survival genetics, DNA Breaks, Double-Stranded drug effects, DNA Damage drug effects, Humans, Signal Transduction genetics, Urinary Bladder Neoplasms pathology, Urothelium drug effects, Urothelium metabolism, Urothelium pathology, Antineoplastic Agents therapeutic use, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell genetics, Cisplatin therapeutic use, Drug Resistance, Neoplasm genetics, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms genetics
- Abstract
Cisplatin (CisPt) is frequently used in the therapy of urothelial carcinoma (UC). Its therapeutic efficacy is limited by inherent or acquired drug resistance. Here, we comparatively investigated the CisPt-induced response of two different parental urothelial carcinoma cell lines (RT-112, J-82) with that of respective drug resistant variants (RT-112R, J-82R) obtained upon month-long CisPt selection. Parental RT-112 cells were ~2.5 fold more resistant to CisPt than J-82 cells and showed a different expression pattern of CisPt-related resistance factors. CisPt resistant RT-112R and J-82R variants revealed a 2-3-fold increased CisPt resistance as compared to their corresponding parental counterparts. Acquired CisPt resistance was accompanied by morphological alterations resembling epithelial mesenchymal transition (EMT). RT-112R cells revealed lower apoptotic frequency and more pronounced G2/M arrest following CisPt exposure than RT-112 cells, whereas no differences in death induction were observed between J-82 and J-82R cells. CisPt resistant J-82R cells however were characterized by a reduced formation of CisPt-induced DNA damage and related DNA damage response (DDR) as compared to J-82 cells. Such difference was not observed between RT-112R and RT-112 cells. J-82R cells showed an enhanced sensitivity to pharmacological inhibition of checkpoint kinase 1 (Chk1) and, moreover, could be re-sensitized to CisPt upon Chk1 inhibition. Based on the data we suggest that mechanisms of acquired CisPt resistance of individual UC cells are substantially different, with apoptosis- and DDR-related mechanisms being of particular relevance. Moreover, the findings indicate that targeting of Chk1 might be useful to overcome acquired CisPt resistance of certain subtypes of UC., Competing Interests: There are no potential conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
22. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
- Author
-
Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, and Sonpavde G
- Subjects
- Aged, Carcinoma, Transitional Cell secondary, Disease-Free Survival, Female, Humans, Liver Neoplasms secondary, Male, Middle Aged, Prognosis, Urologic Neoplasms pathology, Carcinoma, Transitional Cell drug therapy, Nomograms, Urologic Neoplasms drug therapy
- Abstract
Objective: To study the impact of the prognostic factors liver metastasis (LM), anaemia (haemoglobin [Hb] <10 g/dL), Eastern Cooperative Oncology Group performance status (ECOG-PS) ≥1 and time from previous chemotherapy (TFPC) on the activity of second-line therapy for advanced urothelial carcinoma (UC)., Patients and Methods: Twelve phase II trials evaluating second-line chemotherapy and/or biological characteristics (n = 748) in patients with progressive disease were pooled. Progression-free survival (PFS) was defined as tumour progression or death from any cause. The PFS rate at 6 months (PFS6) was defined from the date of registration and calculated using the Kaplan-Meier method. Response rate (RR) was defined using Response Evaluation Criteria in Solid Tumours (RECIST) 1.0. A nomogram predicting PFS6 was constructed using the rms software package in R (http://www.r-project.org)., Results: Data regarding progression, anaemia, LM, ECOG-PS and TFPC were available from 570 patients in nine phase II trials. The overall median PFS was 2.7 months, PFS6 was 22.2% (95% confidence interval 18.8-25.9) and the RR was 17.5% (95% CI: 14.5-20.9%). For every unit increase in risk group, the hazard of progression in 6 months increased by 41% and the odds of response decreased by 48%. A nomogram was constructed to predict PFS6 on an individual patient level. The model was internally validated and was shown to have acceptable calibration performance., Conclusions: The RR and PFS6 vary as a function of baseline prognostic factors in patients receiving second-line therapy for advanced UC. A nomogram incorporating prognostic factors facilitates the evaluation of outcomes across phase II trials enrolling heterogeneous populations and helps select suitable agents for phase III testing., (© 2013 The Authors. BJU International © 2013 BJU International.)
- Published
- 2014
- Full Text
- View/download PDF
23. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database
- Author
-
Moschini, Marco, Xylinas, Evanguelos, Zamboni, Stefania, Mattei, Agostino, Niegisch, Günter, Yu, Evan Y., Bamias, Aristotle, Agarwal, Neeraj, Sridhar, Srikala S., Sternberg, Cora N., Vaishampayan, Ulka N., Rosenberg, Jonathan E., Bellmunt Molins, Joaquim, 1959, Galsky, Matthew D., Montorsi, Francesco, Necchi, Andrea, RISC Investigators, Moschini, Marco, Xylinas, Evanguelo, Zamboni, Stefania, Mattei, Agostino, Niegisch, Günter, Yu, Evan Y, Bamias, Aristoteli, Agarwal, Neeraj, Sridhar, Srikala S, Sternberg, Cora N, Vaishampayan, Ulka N, Rosenberg, Jonathan E, Bellmunt, Joaquim, Galsky, Matthew D, Montorsi, Francesco, and Necchi, Andrea
- Subjects
medicine.medical_specialty ,Databases, Factual ,SUDEP ,Epidemiology ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Interquartile range ,medicine ,Prevalence ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Metastasis ,Mortality ,Aged ,Retrospective Studies ,Chemotherapy ,Carcinoma, Transitional Cell ,Bladder cancer ,Epilepsy ,Proportional hazards model ,business.industry ,Hazard ratio ,Near-SUDEP ,Local treatment ,Middle Aged ,medicine.disease ,Primary tumor ,Carboplatin ,Surgery ,Radical cystectomy ,Oncology ,chemistry ,Spain ,030220 oncology & carcinogenesis ,Metastatic ,Urothelial carcinoma ,business - Abstract
Background The effect of local treatment on survival in advanced-stage patients has gained interest in several malignancies; however, limited data exist regarding urothelial carcinoma (UC). Objective To test the impact of surgery of the primary tumor site on cancer-specific mortality (CSM) and overall mortality (OM) in patients affected by metastatic UC. Design, setting, and participants Individual patient-level data from a multicenter collaboration, including metastatic UC patients treated with first-line cisplatin- or carboplatin-based chemotherapy administered between January 2006 and January 2011 from hospitals in the USA, Europe, Israel, and Canada. Outcome measurements and statistical analysis Univariable and multivariable Cox regression analyses were used to assess the effect of surgery on CSM and OM in patients affected by metastatic UC using 3-mo landmark analyses. Subgroup analyses were performed on the basis of the number of metastasis sites involved and including only patients treated with surgery before the start of chemotherapy. Results and limitations Of the 326 patients included in the study, 47 (14%) were treated with surgery of the primary tumor site. Median (interquartile range) follow-up was 43 (33–45) mo. Of the patients treated with surgery, 28 (60%) were affected by a primary bladder cancer and 19 (40%) by a primary upper urinary tract tumor. On multivariable analyses, surgery was associated with a protective effect on CSM (hazard ratio [HR]: 0.59, confidence interval [CI]: 0.35–0.98, p = 0.04) and OM (HR: 0.45, CI: 0.37–0.99, p = 0.04) compared with patients treated with chemotherapy only. Similar results were found considering patients only surgically treated before the start of chemotherapy. After stratifying according to the number of metastatic sites, surgery has an effect on survival in patients with only one metastatic site, while no survival benefit was observed in patients with two or more metastatic sites. The study is limited by its retrospective nature. Conclusions We found that surgery of the primary tumor site is associated with improved survival in patients with metastatic UC who received standard chemotherapy. This effect disappears in patients affected by two or more metastatic sites. Our results need to be validated in a high-quality prospective trial. Patient summary In our multicenter, retrospective series, surgery in metastatic urothelial cancer patients improve survival compared with patients treated with chemotherapy only. This effect was evident in patients with limited disease extent, identified as one metastatic site.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.